Panel Discussion - Problems in the Cancer Genomic Medicine

Chikashi Ishioka, Manabu Muto, Shinichi Yachida, Hidekazu Shirota, Akira Hirasawa, Kiyoshi Miyagawa, Kazuto Ashizawa, Ichiro Kinoshita, Hiroshi Nishihara, Nariaki Matsuura, Akihiro Sakurai

Research output: Contribution to journalArticlepeer-review


About 4 and a half years have passed since"Cancer Genome Medicine"was first mentioned in the Third Phase of the Basic Plan to Promote Cancer Control Programs that started in October 2017. Currently, cancer genomic medicine is being carried out by the cancer gene panel test, which is covered by public insurance, mainly at the 12 Cancer Genome Medicine Core Center Hospital designated nationwide by the Ministry of Health, Labor, and Welfare in Japan. Cancer genomic medicine has come to be positioned as a standard medical treatment. However, there are various challenges in operating an expert panel that professionally examines the results of the gene panel tests and reports treatment recommendations and secondary findings that suggest hereditary tumors. In addition, there is an urgent need to disseminate and educate healthcare professionals and patients about cancer genomic medicine. In this panel discussion on January 14, 2022, 10 panelists discussed how to solve these issues and the prospects for the future.

Original languageEnglish
Pages (from-to)1014-1017
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number9
Publication statusPublished - 2022 Sept 1

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Panel Discussion - Problems in the Cancer Genomic Medicine'. Together they form a unique fingerprint.

Cite this